Trevena, Inc. Banner Image

Trevena, Inc. has reached its limit for free report views

Work for Trevena, Inc.? Upgrade Your Profile and unlock all your annual reports.

Trevena, Inc.

  • Ticker TRVN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Trevena, Inc. Logo Image
  • 11-50 Employees
  • Based in Chesterbrook, Pennsylvania
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYKâ„¢ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments areMore inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.
Trevena, Inc.

Most Recent Annual Report

Trevena, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Trevena, Inc. has reached its limit for free report views.

Older/Archived Annual Reports